Why Choose KromaTiD?

KromaTiD is not just shaping the future of gene editing characterization; we are redefining it. We lead the way with novel single-cell structural genomic analysis tailored for cell and gene therapy companies. With an unwavering commitment to best-in-class science, we are dedicated to collaborating seamlessly with our partners to deliver state-of-the-art data, providing genome integrity insights that support research advancements. As the leader in genomic integrity analysis, it is our mission to support your journey from early research to the release of cell and gene therapy products. At KromaTiD, our data and novel technology can help de-risk and accelerate your programs, bringing hope and critical life-saving therapies to patients in need.

Our journey began in 2016 with our dGH chromatid paints, used to assess radiation damage from nuclear exposure and spaceflight. Today, the dGH platform remains vital to our cell and gene therapy customers and is trusted by NASA for ongoing research, enabling direct analysis of genomic integrity while identifying complex structural rearrangements that conventional PCR and sequencing platforms may miss.

At KromaTiD, we believe in the power of collaboration. We work closely with your team to understand your unique challenges and goals, providing tailored solutions that integrate seamlessly into your workflow. Our experts are dedicated to supporting you at every stage, from initial research to clinical trials, ensuring that you have the insights and data needed to advance your therapies with confidence.

Join us in pioneering the next generation of genomic solutions. Together, we can achieve unparalleled precision and reliability in gene editing, driving the future of personalized medicine and transformative treatments for patients.